KPV vs Thymosin Alpha-1
Both KPV and Thymosin Alpha-1 are used for anti-inflammatory. Here's how their evidence, dosing, and regulatory status actually compare.
KPV
Evidence C+α-MSH Tripeptide KPV
The C-terminal tripeptide of α-MSH with documented anti-inflammatory activity in IBD and dermatitis preclinical models. Frequently delivered orally and topically.
View full KPV profile →Thymosin Alpha-1
Evidence AThymosin Alpha-1 (Tα1)
A 28-amino-acid thymic peptide that matures and modulates T-cells. Used internationally as an adjunct in hepatitis, sepsis, and immune-compromised cancer care.
View full Thymosin Alpha-1 profile →Side-by-Side
| Attribute | KPV | Thymosin Alpha-1 |
|---|---|---|
| Evidence Grade | C+ | A |
| FDA Status | Not FDA-approved — research peptide | Approved in 35+ countries for hepatitis B/C, immune support; not FDA-approved in US (orphan-drug designations) |
| Typical Dose | 200–500 mcg orally or topical (research only) | 1.6 mg twice weekly (subcutaneous) |
| Clinics Indexed | 26 | 192 |
| Categories | anti-inflammatory, gut-health, skin | immune, anti-inflammatory |
Key reported benefits — KPV
- ✓GI inflammation reduction
- ✓Skin inflammation reduction
- ✓Antimicrobial activity
Key reported benefits — Thymosin Alpha-1
- ✓T-cell maturation
- ✓Antiviral immunity
- ✓Tumor immune support
- ✓Sepsis adjunct
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.